Project description
An innovative implant for relieving enlarged prostate symptoms
Benign prostatic hyperplasia (BPH), also known as enlarged prostate, is a common condition that affects men over the age of 50 and involves the non-cancerous enlargement of the prostate gland. The enlargement of the prostate can constrict the urethra, leading to various urinary symptoms. Funded by the European Innovation Council, the MPRD project aims to relieve the symptoms of BPH through an implant that improves urine flow. The innovative device can be implanted through a minimally invasive 10-minute approach in the clinic under local anaesthetic and is permanent. Preliminary clinical trial data in patients are encouraging and the MPRD team aim to undertake studies in leading medical centres in Europe, and an FDA study in the US.
Objective
Butterfly Medical, a medical-device start-up, is developing a fast, simple, and minimally invasive alternative treatment to medication and surgery used for Benign Prostate Hyperplasia (BPH) treatment. Butterfly’s innovative device transfers the procedure from the operating room to the clinic, with the device being placed in 6 to 8 minutes, in doctor’s office, under local anaesthesia.
Butterfly’s unique anatomically shaped proprietary nitinol implant is positioned in the prostatic urethra in order to open the urine path in the prostate for improved urine flow thereby relieving BPH symptoms. Implant doesn’t require any resection, cutting, or ablation of prostatic tissue.
FIH clinical trials involving 85 patients performed in leading medical centres in Israel show a high degree of safety and effectiveness. Through this EIC project, Butterfly will undertake post-marketing studies in leading medical centres in Europe, and pivotal FDA study in the US.
Fields of science
Keywords
Programme(s)
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Funding Scheme
HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended FinanceCoordinator
20692 YOKNEAM
Israel
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.